Logo image
Back
Physician-Predicted Prognosis and Palliative Radiotherapy Treatment Utilization at the End of Life: An Audit of a Large Cancer Center Network
Journal article   Open access   Peer reviewed

Physician-Predicted Prognosis and Palliative Radiotherapy Treatment Utilization at the End of Life: An Audit of a Large Cancer Center Network

Adrianna E. Mojica-Márquez, Joshua L. Rodríguez-López, Ankur K. Patel, Diane C. Ling, Malolan S. Rajagopalan and Sushil Beriwal
Journal of pain and symptom management, v 60(5), pp 898-905
Nov 2020
DOI: https://doi.org/10.1016/j.jpainsymman.2020.06.022
PMID: 32599149
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1016/j.jpainsymman.2020.06.022View
Published, Version of Record (VoR) Restricted

Abstract

advanced cancer clinical pathways end of life Palliative radiotherapy survival
At our institution, clinical pathways capture physicians’ prognostication of patients being evaluated for palliative radiotherapy. We hypothesize a low utilization rate of long-course radiotherapy (LCRT) and stereotactic ablative radiotherapy (SAbR) among patients seen at the end of life, especially those with physician-predicted poor prognosis. To analyze utilization rates and predictors of LCRT and SAbR at the end of life. A retrospective review was conducted on patients who were evaluated for palliative radiotherapy between January 2017 and August 2019 and died within 90 days of consultation. Binary logistic regression was used to identify predictors for utilization of LCRT (≥10 fractions) and SAbR. A total of 1608 patients were identified, of which 1038 patients (64.6%) were predicted to die within a year. Six hundred ninety-three patients (66.8%) out of 1038 were prescribed LCRT or SAbR. On a multivariate analysis, patients were less likely to be prescribed LCRT if treated at an academic site (odds ratio [OR], 0.30; 95% confidence interval [CI], 0.23–0.39; P < 0.01) and treated for bone metastases (OR, 0.08; 95% CI, 0.05–0.11; P < 0.01) or other nonbrain/nonbone metastases (OR, 0.19; 95% CI, 0.13–0.30; P < 0.01). SAbR was less likely to be prescribed among patients predicted to die within a year (OR, 0.09; 95% CI, 0.06–0.16; P < 0.01), treated for bone metastases (OR, 0.13; 95% CI, 0.07–0.22; P < 0.01), with poor performance status (OR, 0.51; 95% CI, 0.31–0.85; P = 0.01), and with a breast primary (OR, 0.35; 95% CI, 0.15–0.82; P = 0.02). Although most patients were predicted to have a limited prognosis, LCRT and SAbR were commonly prescribed at the end of life.

Metrics

9 Record Views
2 citations in Web of Science
2 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Clinical Neurology
Health Care Sciences & Services
Logo image